Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antibodies, Viral | 143 | 2024 | 3213 | 13.410 |
Why?
|
Immunity, Humoral | 59 | 2024 | 609 | 12.040 |
Why?
|
HIV Antibodies | 64 | 2024 | 1337 | 11.170 |
Why?
|
Antibodies, Neutralizing | 110 | 2024 | 2011 | 9.240 |
Why?
|
Immunoglobulin Fc Fragments | 39 | 2024 | 287 | 8.700 |
Why?
|
AIDS Vaccines | 44 | 2023 | 898 | 7.400 |
Why?
|
HIV-1 | 115 | 2024 | 6948 | 7.210 |
Why?
|
Immunoglobulin G | 95 | 2024 | 4559 | 7.090 |
Why?
|
Killer Cells, Natural | 54 | 2024 | 2209 | 6.300 |
Why?
|
HIV Infections | 148 | 2024 | 17532 | 6.070 |
Why?
|
Receptors, Fc | 27 | 2024 | 537 | 5.120 |
Why?
|
Ebolavirus | 18 | 2024 | 250 | 4.260 |
Why?
|
Vaccination | 54 | 2025 | 3435 | 4.180 |
Why?
|
Antibodies, Bacterial | 19 | 2025 | 1477 | 4.100 |
Why?
|
Antibodies | 21 | 2023 | 2421 | 4.040 |
Why?
|
HIV | 24 | 2022 | 1588 | 3.920 |
Why?
|
Hemorrhagic Fever, Ebola | 19 | 2024 | 424 | 3.900 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 25 | 2021 | 306 | 3.860 |
Why?
|
Viral Vaccines | 20 | 2024 | 596 | 3.510 |
Why?
|
Mycobacterium tuberculosis | 21 | 2025 | 1911 | 3.480 |
Why?
|
Phagocytosis | 28 | 2022 | 1526 | 3.460 |
Why?
|
Receptors, IgG | 26 | 2024 | 562 | 3.240 |
Why?
|
Vaccines | 15 | 2023 | 842 | 3.120 |
Why?
|
Influenza Vaccines | 10 | 2024 | 780 | 3.090 |
Why?
|
Tuberculosis | 20 | 2025 | 2011 | 3.040 |
Why?
|
Latent Tuberculosis | 7 | 2022 | 223 | 3.030 |
Why?
|
Immunity, Innate | 32 | 2025 | 3079 | 3.020 |
Why?
|
Antibody Formation | 17 | 2024 | 1392 | 2.780 |
Why?
|
Simian immunodeficiency virus | 22 | 2022 | 812 | 2.580 |
Why?
|
Viral Load | 43 | 2024 | 3385 | 2.550 |
Why?
|
HIV Antigens | 9 | 2021 | 328 | 2.460 |
Why?
|
Immunoglobulin Fab Fragments | 7 | 2021 | 446 | 2.450 |
Why?
|
Polysaccharides | 15 | 2024 | 1020 | 2.430 |
Why?
|
Cross Reactions | 13 | 2024 | 826 | 2.340 |
Why?
|
Glycosylation | 24 | 2022 | 1099 | 2.310 |
Why?
|
Receptors, KIR | 15 | 2016 | 114 | 2.250 |
Why?
|
Immunization, Passive | 9 | 2022 | 618 | 2.210 |
Why?
|
Influenza, Human | 8 | 2024 | 1543 | 2.210 |
Why?
|
Respiratory Syncytial Virus, Human | 4 | 2024 | 150 | 2.160 |
Why?
|
Macaca mulatta | 50 | 2025 | 2341 | 2.120 |
Why?
|
Virus Replication | 21 | 2021 | 2457 | 2.030 |
Why?
|
Respiratory Syncytial Virus Infections | 4 | 2024 | 366 | 1.940 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 17 | 2021 | 543 | 1.880 |
Why?
|
Malaria Vaccines | 5 | 2024 | 165 | 1.870 |
Why?
|
Pregnancy Complications, Infectious | 10 | 2024 | 2183 | 1.810 |
Why?
|
SAIDS Vaccines | 9 | 2020 | 144 | 1.740 |
Why?
|
Immunoglobulin A | 11 | 2023 | 992 | 1.740 |
Why?
|
Antibodies, Monoclonal | 30 | 2024 | 9244 | 1.700 |
Why?
|
High-Throughput Screening Assays | 7 | 2021 | 938 | 1.580 |
Why?
|
Immunoglobulin M | 11 | 2023 | 1527 | 1.540 |
Why?
|
CD4-Positive T-Lymphocytes | 38 | 2023 | 4410 | 1.510 |
Why?
|
Primates | 9 | 2023 | 519 | 1.490 |
Why?
|
Immunity | 10 | 2023 | 1002 | 1.480 |
Why?
|
Viremia | 17 | 2022 | 727 | 1.480 |
Why?
|
Humans | 381 | 2025 | 766812 | 1.440 |
Why?
|
Ebola Vaccines | 4 | 2023 | 25 | 1.420 |
Why?
|
Histocompatibility Antigens Class I | 14 | 2022 | 1362 | 1.410 |
Why?
|
Orthomyxoviridae | 2 | 2024 | 148 | 1.400 |
Why?
|
Placenta | 9 | 2022 | 1726 | 1.370 |
Why?
|
Antigen-Antibody Complex | 6 | 2022 | 512 | 1.370 |
Why?
|
HIV Envelope Protein gp120 | 11 | 2020 | 923 | 1.360 |
Why?
|
Coronavirus Infections | 11 | 2020 | 3110 | 1.330 |
Why?
|
Pneumonia, Viral | 11 | 2020 | 3232 | 1.310 |
Why?
|
Malaria | 4 | 2023 | 1246 | 1.270 |
Why?
|
BCG Vaccine | 6 | 2025 | 381 | 1.270 |
Why?
|
Milk, Human | 4 | 2021 | 490 | 1.240 |
Why?
|
Tuberculosis, Pulmonary | 4 | 2025 | 836 | 1.220 |
Why?
|
Adjuvants, Immunologic | 10 | 2021 | 996 | 1.210 |
Why?
|
Malaria, Falciparum | 5 | 2024 | 1075 | 1.190 |
Why?
|
Lymphocyte Subsets | 5 | 2016 | 313 | 1.180 |
Why?
|
B-Lymphocytes | 22 | 2024 | 4787 | 1.170 |
Why?
|
Complement System Proteins | 9 | 2024 | 738 | 1.160 |
Why?
|
Epitopes | 23 | 2022 | 2526 | 1.110 |
Why?
|
Host-Pathogen Interactions | 15 | 2022 | 1466 | 1.100 |
Why?
|
Antigens, Viral | 14 | 2024 | 995 | 1.100 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 8 | 2020 | 381 | 1.090 |
Why?
|
CD8-Positive T-Lymphocytes | 27 | 2022 | 4652 | 1.070 |
Why?
|
Immunity, Maternally-Acquired | 3 | 2024 | 112 | 1.050 |
Why?
|
Animals | 130 | 2025 | 168939 | 1.050 |
Why?
|
Viral Envelope Proteins | 13 | 2024 | 640 | 1.050 |
Why?
|
Dysentery, Bacillary | 2 | 2024 | 73 | 0.990 |
Why?
|
Immune System | 5 | 2024 | 800 | 0.980 |
Why?
|
Respiratory Syncytial Virus Vaccines | 2 | 2023 | 37 | 0.970 |
Why?
|
Monocytes | 13 | 2022 | 2599 | 0.970 |
Why?
|
Saponins | 2 | 2021 | 47 | 0.950 |
Why?
|
Neutrophils | 12 | 2024 | 3782 | 0.940 |
Why?
|
Antigens, Bacterial | 6 | 2023 | 1148 | 0.940 |
Why?
|
HIV Core Protein p24 | 5 | 2020 | 245 | 0.930 |
Why?
|
Tuberculosis, Meningeal | 1 | 2024 | 49 | 0.900 |
Why?
|
Immune Evasion | 6 | 2016 | 375 | 0.890 |
Why?
|
Immunity, Cellular | 17 | 2023 | 1560 | 0.860 |
Why?
|
Adaptive Immunity | 7 | 2023 | 734 | 0.850 |
Why?
|
Lymphocyte Activation | 21 | 2020 | 5502 | 0.850 |
Why?
|
Vaccines, DNA | 6 | 2021 | 279 | 0.840 |
Why?
|
Antibody Affinity | 8 | 2021 | 251 | 0.820 |
Why?
|
RNA, Viral | 16 | 2022 | 2867 | 0.810 |
Why?
|
Cytokines | 19 | 2025 | 7438 | 0.810 |
Why?
|
Rubella | 1 | 2022 | 55 | 0.800 |
Why?
|
Complement Activation | 4 | 2024 | 447 | 0.790 |
Why?
|
Shigella | 1 | 2022 | 69 | 0.780 |
Why?
|
Adenoviridae | 6 | 2021 | 1093 | 0.780 |
Why?
|
Immunologic Techniques | 2 | 2019 | 212 | 0.780 |
Why?
|
Alphavirus | 4 | 2023 | 9 | 0.770 |
Why?
|
Nucleocapsid Proteins | 2 | 2023 | 75 | 0.750 |
Why?
|
Virus Latency | 4 | 2021 | 359 | 0.740 |
Why?
|
Female | 145 | 2025 | 396532 | 0.740 |
Why?
|
Squalene | 2 | 2021 | 36 | 0.730 |
Why?
|
HLA-C Antigens | 3 | 2016 | 146 | 0.730 |
Why?
|
Vaccines, Synthetic | 13 | 2023 | 620 | 0.720 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 10 | 2023 | 3803 | 0.710 |
Why?
|
Systems Analysis | 2 | 2022 | 168 | 0.700 |
Why?
|
Antigens | 8 | 2022 | 1442 | 0.700 |
Why?
|
Fetal Blood | 3 | 2024 | 1367 | 0.700 |
Why?
|
Interferon-gamma | 22 | 2025 | 3157 | 0.690 |
Why?
|
Polysorbates | 1 | 2020 | 46 | 0.680 |
Why?
|
Vaccinia virus | 8 | 2024 | 328 | 0.680 |
Why?
|
Plasma | 3 | 2022 | 583 | 0.670 |
Why?
|
Genetic Vectors | 11 | 2023 | 3401 | 0.660 |
Why?
|
Electrophoresis, Capillary | 2 | 2020 | 63 | 0.660 |
Why?
|
Antigen-Antibody Reactions | 1 | 2019 | 341 | 0.650 |
Why?
|
HLA Antigens | 6 | 2014 | 1339 | 0.650 |
Why?
|
Immunoassay | 6 | 2021 | 744 | 0.640 |
Why?
|
Tuberculosis Vaccines | 1 | 2019 | 48 | 0.630 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2016 | 2204 | 0.630 |
Why?
|
Flow Cytometry | 20 | 2019 | 5890 | 0.630 |
Why?
|
Influenza A Virus, H5N1 Subtype | 1 | 2020 | 117 | 0.630 |
Why?
|
Viral Fusion Proteins | 4 | 2024 | 100 | 0.630 |
Why?
|
Antibodies, Protozoan | 5 | 2024 | 251 | 0.620 |
Why?
|
Maternal-Fetal Exchange | 1 | 2020 | 453 | 0.620 |
Why?
|
Serology | 1 | 2017 | 7 | 0.600 |
Why?
|
Pandemics | 19 | 2023 | 8734 | 0.600 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.600 |
Why?
|
Antigens, CD | 9 | 2020 | 4033 | 0.600 |
Why?
|
Yellow Fever Vaccine | 1 | 2018 | 38 | 0.600 |
Why?
|
Young Adult | 43 | 2025 | 59939 | 0.590 |
Why?
|
Receptors, KIR3DS1 | 4 | 2016 | 9 | 0.590 |
Why?
|
Adult | 86 | 2025 | 223305 | 0.580 |
Why?
|
Pneumococcal Infections | 1 | 2022 | 529 | 0.570 |
Why?
|
Male | 115 | 2025 | 364154 | 0.560 |
Why?
|
Systems Biology | 2 | 2018 | 481 | 0.560 |
Why?
|
Membrane Glycoproteins | 10 | 2022 | 3702 | 0.560 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2021 | 1353 | 0.560 |
Why?
|
Alleles | 10 | 2022 | 6896 | 0.550 |
Why?
|
Gene Products, env | 5 | 2020 | 250 | 0.550 |
Why?
|
Phagocytes | 3 | 2019 | 292 | 0.550 |
Why?
|
Antigen Presentation | 3 | 2019 | 1250 | 0.550 |
Why?
|
Nucleocapsid | 5 | 2023 | 61 | 0.540 |
Why?
|
Streptococcus pneumoniae | 1 | 2022 | 764 | 0.540 |
Why?
|
Immunization | 7 | 2020 | 1218 | 0.540 |
Why?
|
Glycoproteins | 9 | 2024 | 2201 | 0.540 |
Why?
|
Virus Diseases | 3 | 2020 | 721 | 0.540 |
Why?
|
Protein Processing, Post-Translational | 3 | 2020 | 1965 | 0.540 |
Why?
|
Carrier State | 2 | 2021 | 530 | 0.530 |
Why?
|
Cell Degranulation | 4 | 2019 | 276 | 0.530 |
Why?
|
T-Lymphocytes, Helper-Inducer | 7 | 2022 | 975 | 0.530 |
Why?
|
Antibodies, Blocking | 2 | 2014 | 250 | 0.530 |
Why?
|
Inflammation | 9 | 2023 | 10863 | 0.530 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 657 | 0.530 |
Why?
|
Receptors, KIR3DL1 | 4 | 2012 | 27 | 0.530 |
Why?
|
Antibody Specificity | 7 | 2021 | 1062 | 0.520 |
Why?
|
RNA, Messenger | 15 | 2024 | 12795 | 0.520 |
Why?
|
Evolution, Molecular | 3 | 2015 | 1893 | 0.520 |
Why?
|
Toll-Like Receptor 7 | 5 | 2018 | 169 | 0.510 |
Why?
|
Dendritic Cells | 8 | 2015 | 2747 | 0.510 |
Why?
|
Immunoglobulin Isotypes | 3 | 2021 | 158 | 0.500 |
Why?
|
AIDS Serodiagnosis | 1 | 2017 | 220 | 0.490 |
Why?
|
Mice, Inbred BALB C | 13 | 2024 | 6225 | 0.480 |
Why?
|
Pregnancy | 20 | 2024 | 30236 | 0.480 |
Why?
|
HLA-B Antigens | 3 | 2013 | 330 | 0.470 |
Why?
|
Cell Separation | 4 | 2016 | 1718 | 0.460 |
Why?
|
Infant, Newborn | 17 | 2024 | 26387 | 0.460 |
Why?
|
Systemic Inflammatory Response Syndrome | 5 | 2023 | 621 | 0.460 |
Why?
|
Guinea Pigs | 9 | 2023 | 1309 | 0.450 |
Why?
|
Chikungunya virus | 4 | 2023 | 56 | 0.450 |
Why?
|
Cohort Studies | 25 | 2024 | 41706 | 0.440 |
Why?
|
CA-125 Antigen | 1 | 2016 | 282 | 0.440 |
Why?
|
Middle Aged | 61 | 2025 | 223267 | 0.430 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2015 | 1802 | 0.430 |
Why?
|
Cytotoxicity, Immunologic | 6 | 2018 | 1352 | 0.430 |
Why?
|
Immunization, Secondary | 6 | 2022 | 373 | 0.430 |
Why?
|
Anti-Retroviral Agents | 11 | 2023 | 1787 | 0.420 |
Why?
|
Mice | 43 | 2024 | 81898 | 0.420 |
Why?
|
Communicable Diseases | 2 | 2023 | 872 | 0.420 |
Why?
|
Endemic Diseases | 2 | 2024 | 190 | 0.410 |
Why?
|
Receptors, Complement 3d | 1 | 2013 | 117 | 0.410 |
Why?
|
Infant, Premature | 1 | 2022 | 2120 | 0.410 |
Why?
|
Lactation | 4 | 2022 | 392 | 0.400 |
Why?
|
Protein Binding | 15 | 2022 | 9326 | 0.400 |
Why?
|
Alum Compounds | 4 | 2021 | 35 | 0.400 |
Why?
|
Neutralization Tests | 5 | 2022 | 736 | 0.390 |
Why?
|
Protein Engineering | 4 | 2024 | 554 | 0.390 |
Why?
|
South Africa | 9 | 2024 | 1873 | 0.390 |
Why?
|
Immunophenotyping | 7 | 2021 | 1867 | 0.390 |
Why?
|
Bacterial Infections | 1 | 2020 | 1390 | 0.380 |
Why?
|
Uganda | 3 | 2024 | 1353 | 0.380 |
Why?
|
Hemagglutinins | 2 | 2024 | 111 | 0.380 |
Why?
|
Disease Models, Animal | 23 | 2021 | 18329 | 0.370 |
Why?
|
Neutrophil Activation | 3 | 2021 | 180 | 0.370 |
Why?
|
Macaca | 6 | 2024 | 413 | 0.370 |
Why?
|
Genotype | 8 | 2021 | 13036 | 0.360 |
Why?
|
Immunologic Memory | 7 | 2022 | 1377 | 0.360 |
Why?
|
Lymphocyte Count | 6 | 2012 | 794 | 0.350 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2012 | 418 | 0.350 |
Why?
|
Adolescent | 29 | 2025 | 88902 | 0.350 |
Why?
|
Matrix Metalloproteinases | 2 | 2010 | 391 | 0.340 |
Why?
|
Vaccines, Conjugate | 2 | 2022 | 334 | 0.340 |
Why?
|
Sex Characteristics | 2 | 2018 | 2645 | 0.340 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2023 | 163 | 0.340 |
Why?
|
Ligands | 7 | 2016 | 3274 | 0.340 |
Why?
|
Child | 27 | 2023 | 80670 | 0.330 |
Why?
|
Plasmodium falciparum | 5 | 2024 | 1739 | 0.330 |
Why?
|
Hepatitis C, Chronic | 3 | 2015 | 1033 | 0.330 |
Why?
|
Models, Immunological | 5 | 2018 | 517 | 0.330 |
Why?
|
Infant | 17 | 2024 | 36459 | 0.330 |
Why?
|
Marburgvirus | 2 | 2020 | 19 | 0.330 |
Why?
|
Intestinal Mucosa | 3 | 2021 | 3041 | 0.320 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 4 | 2014 | 29 | 0.320 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 812 | 0.310 |
Why?
|
Disease Progression | 13 | 2024 | 13642 | 0.300 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2021 | 361 | 0.300 |
Why?
|
Viral Proteins | 5 | 2021 | 1801 | 0.290 |
Why?
|
Epitope Mapping | 5 | 2021 | 301 | 0.290 |
Why?
|
Immunoglobulin Constant Regions | 3 | 2017 | 58 | 0.290 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 3 | 2014 | 94 | 0.290 |
Why?
|
Carbohydrate Sequence | 2 | 2018 | 411 | 0.280 |
Why?
|
HIV Envelope Protein gp41 | 3 | 2020 | 306 | 0.280 |
Why?
|
Toll-Like Receptors | 4 | 2021 | 582 | 0.280 |
Why?
|
Ferrets | 4 | 2023 | 181 | 0.280 |
Why?
|
Gene Expression | 9 | 2021 | 7585 | 0.280 |
Why?
|
Adoptive Transfer | 5 | 2021 | 828 | 0.280 |
Why?
|
HIV Seropositivity | 4 | 2024 | 962 | 0.280 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2255 | 0.270 |
Why?
|
Immunologic Factors | 4 | 2021 | 1594 | 0.270 |
Why?
|
T-Lymphocyte Subsets | 6 | 2021 | 1814 | 0.270 |
Why?
|
Case-Control Studies | 13 | 2021 | 22248 | 0.270 |
Why?
|
Cell Line | 14 | 2021 | 15564 | 0.270 |
Why?
|
Gene Products, gag | 3 | 2020 | 317 | 0.270 |
Why?
|
Influenza A virus | 2 | 2020 | 455 | 0.260 |
Why?
|
Germinal Center | 2 | 2020 | 379 | 0.260 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2022 | 617 | 0.260 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2019 | 696 | 0.260 |
Why?
|
DNA, Viral | 5 | 2021 | 2201 | 0.250 |
Why?
|
Serum | 2 | 2020 | 206 | 0.250 |
Why?
|
Time Factors | 16 | 2022 | 40149 | 0.250 |
Why?
|
K562 Cells | 5 | 2012 | 644 | 0.250 |
Why?
|
Leukocytes, Mononuclear | 8 | 2021 | 1852 | 0.250 |
Why?
|
HIV Long-Term Survivors | 3 | 2017 | 140 | 0.250 |
Why?
|
Cricetinae | 4 | 2022 | 2416 | 0.250 |
Why?
|
Aged | 23 | 2024 | 171344 | 0.250 |
Why?
|
Tuberculin Test | 3 | 2023 | 205 | 0.250 |
Why?
|
Human Immunodeficiency Virus Proteins | 3 | 2015 | 56 | 0.250 |
Why?
|
Shigella flexneri | 2 | 2024 | 118 | 0.240 |
Why?
|
Vaccines, Inactivated | 2 | 2024 | 186 | 0.240 |
Why?
|
Shigella sonnei | 1 | 2024 | 7 | 0.240 |
Why?
|
Macrophage Activation | 2 | 2019 | 554 | 0.240 |
Why?
|
Virus Release | 2 | 2021 | 35 | 0.240 |
Why?
|
Interleukin-10 | 1 | 2010 | 1182 | 0.230 |
Why?
|
Adaptation, Physiological | 1 | 2011 | 1312 | 0.230 |
Why?
|
Severity of Illness Index | 9 | 2021 | 15912 | 0.230 |
Why?
|
Up-Regulation | 5 | 2023 | 4143 | 0.230 |
Why?
|
Hepatitis C | 2 | 2014 | 1595 | 0.230 |
Why?
|
Antigens, Protozoan | 2 | 2023 | 315 | 0.230 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2006 | 415 | 0.230 |
Why?
|
Vero Cells | 6 | 2021 | 486 | 0.230 |
Why?
|
Liver | 3 | 2021 | 7571 | 0.220 |
Why?
|
Arenaviridae | 1 | 2023 | 5 | 0.220 |
Why?
|
Aging | 3 | 2023 | 8728 | 0.220 |
Why?
|
Antibody-Dependent Enhancement | 2 | 2020 | 15 | 0.220 |
Why?
|
Mesocricetus | 2 | 2021 | 256 | 0.220 |
Why?
|
Research Personnel | 1 | 2009 | 589 | 0.220 |
Why?
|
Amino Acid Sequence | 13 | 2021 | 13411 | 0.220 |
Why?
|
Phosphoproteins | 3 | 2024 | 2448 | 0.220 |
Why?
|
Cell Communication | 1 | 2011 | 1660 | 0.220 |
Why?
|
Merozoite Surface Protein 1 | 1 | 2023 | 36 | 0.220 |
Why?
|
Merozoites | 1 | 2023 | 60 | 0.220 |
Why?
|
Vaccines, Subunit | 2 | 2021 | 159 | 0.210 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily C | 2 | 2014 | 38 | 0.210 |
Why?
|
Alphavirus Infections | 2 | 2021 | 20 | 0.210 |
Why?
|
Gene Products, pol | 2 | 2020 | 43 | 0.210 |
Why?
|
Survivors | 4 | 2021 | 2379 | 0.210 |
Why?
|
HEK293 Cells | 7 | 2021 | 4277 | 0.210 |
Why?
|
Viral Regulatory and Accessory Proteins | 2 | 2015 | 151 | 0.210 |
Why?
|
Smallpox Vaccine | 1 | 2023 | 77 | 0.210 |
Why?
|
Filoviridae | 3 | 2019 | 15 | 0.210 |
Why?
|
Cell Membrane | 3 | 2015 | 3642 | 0.210 |
Why?
|
Lassa virus | 1 | 2023 | 99 | 0.210 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 2 | 2014 | 85 | 0.210 |
Why?
|
Chiroptera | 1 | 2023 | 62 | 0.200 |
Why?
|
Schistosomiasis mansoni | 1 | 2023 | 94 | 0.200 |
Why?
|
Belgium | 2 | 2019 | 119 | 0.200 |
Why?
|
Hepatitis D | 1 | 2022 | 23 | 0.200 |
Why?
|
Mucous Membrane | 2 | 2016 | 659 | 0.200 |
Why?
|
Vaccines, Attenuated | 1 | 2024 | 314 | 0.200 |
Why?
|
Lymph Nodes | 4 | 2021 | 3468 | 0.200 |
Why?
|
Virion | 2 | 2021 | 428 | 0.200 |
Why?
|
Anti-HIV Agents | 4 | 2022 | 4561 | 0.200 |
Why?
|
Reproducibility of Results | 5 | 2020 | 20146 | 0.200 |
Why?
|
Vaccinia | 1 | 2022 | 71 | 0.200 |
Why?
|
Coronavirus OC43, Human | 1 | 2021 | 20 | 0.190 |
Why?
|
Sensitivity and Specificity | 7 | 2023 | 14653 | 0.190 |
Why?
|
Single-Chain Antibodies | 1 | 2022 | 114 | 0.190 |
Why?
|
Immunodominant Epitopes | 3 | 2019 | 244 | 0.190 |
Why?
|
Lymph | 1 | 2021 | 78 | 0.190 |
Why?
|
Placebos | 3 | 2022 | 1659 | 0.190 |
Why?
|
Child, Preschool | 10 | 2024 | 42577 | 0.190 |
Why?
|
Immunotherapy | 3 | 2023 | 4747 | 0.190 |
Why?
|
Stearic Acids | 1 | 2021 | 56 | 0.190 |
Why?
|
Chromatography, Affinity | 2 | 2023 | 524 | 0.190 |
Why?
|
Peptides | 4 | 2011 | 4347 | 0.180 |
Why?
|
Conserved Sequence | 3 | 2021 | 1159 | 0.180 |
Why?
|
Tuberculin | 1 | 2020 | 63 | 0.180 |
Why?
|
Markov Chains | 1 | 2024 | 974 | 0.180 |
Why?
|
Typhoid-Paratyphoid Vaccines | 1 | 2021 | 40 | 0.180 |
Why?
|
T-Lymphocytes | 9 | 2021 | 10263 | 0.180 |
Why?
|
Perforin | 2 | 2014 | 167 | 0.180 |
Why?
|
Prospective Studies | 13 | 2024 | 54872 | 0.180 |
Why?
|
Injections, Intramuscular | 2 | 2020 | 551 | 0.180 |
Why?
|
Marburg Virus Disease | 1 | 2020 | 11 | 0.180 |
Why?
|
Hinge Exons | 1 | 2020 | 2 | 0.180 |
Why?
|
Seroepidemiologic Studies | 4 | 2023 | 404 | 0.180 |
Why?
|
Iceland | 1 | 2020 | 183 | 0.170 |
Why?
|
Receptors, Complement | 1 | 2021 | 254 | 0.170 |
Why?
|
Binding Sites | 6 | 2019 | 6013 | 0.170 |
Why?
|
Dengue Virus | 1 | 2022 | 204 | 0.170 |
Why?
|
Drug Discovery | 2 | 2020 | 1065 | 0.170 |
Why?
|
Haptoglobins | 1 | 2021 | 166 | 0.170 |
Why?
|
Endogenous Retroviruses | 1 | 2021 | 111 | 0.170 |
Why?
|
Autoantibodies | 3 | 2023 | 2115 | 0.170 |
Why?
|
Measles | 1 | 2022 | 180 | 0.170 |
Why?
|
Recombinant Proteins | 5 | 2019 | 6507 | 0.170 |
Why?
|
HL-60 Cells | 1 | 2020 | 364 | 0.170 |
Why?
|
Asymptomatic Infections | 1 | 2021 | 136 | 0.170 |
Why?
|
Th1 Cells | 2 | 2019 | 1040 | 0.170 |
Why?
|
Immunoglobulin Class Switching | 1 | 2021 | 289 | 0.170 |
Why?
|
Bacterial Proteins | 3 | 2022 | 3833 | 0.170 |
Why?
|
HIV Integrase Inhibitors | 1 | 2022 | 165 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 204 | 0.170 |
Why?
|
Interleukins | 4 | 2021 | 796 | 0.170 |
Why?
|
Blood Donors | 1 | 2021 | 344 | 0.160 |
Why?
|
Acute Disease | 9 | 2023 | 7240 | 0.160 |
Why?
|
Th2 Cells | 2 | 2019 | 1077 | 0.160 |
Why?
|
Longitudinal Studies | 9 | 2024 | 14762 | 0.160 |
Why?
|
Sierra Leone | 1 | 2020 | 171 | 0.160 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2025 | 757 | 0.160 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2011 | 1900 | 0.160 |
Why?
|
Serologic Tests | 1 | 2021 | 382 | 0.160 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2021 | 213 | 0.160 |
Why?
|
Models, Molecular | 3 | 2019 | 5388 | 0.160 |
Why?
|
Cells, Cultured | 14 | 2020 | 18986 | 0.160 |
Why?
|
Disease Reservoirs | 1 | 2019 | 123 | 0.160 |
Why?
|
Immunoglobulin Fragments | 1 | 2019 | 83 | 0.160 |
Why?
|
Typhoid Fever | 1 | 2021 | 197 | 0.160 |
Why?
|
Computational Biology | 4 | 2020 | 3564 | 0.160 |
Why?
|
Herpesvirus 4, Human | 3 | 2022 | 1080 | 0.160 |
Why?
|
HIV Envelope Protein gp160 | 1 | 2019 | 95 | 0.160 |
Why?
|
Dengue | 1 | 2022 | 258 | 0.160 |
Why?
|
Viral Nonstructural Proteins | 1 | 2020 | 228 | 0.160 |
Why?
|
Membrane Proteins | 1 | 2016 | 7869 | 0.160 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 166 | 0.160 |
Why?
|
Receptors, CCR5 | 3 | 2019 | 491 | 0.160 |
Why?
|
Acyltransferases | 1 | 2020 | 305 | 0.160 |
Why?
|
Lymphocytic Choriomeningitis | 2 | 2016 | 140 | 0.160 |
Why?
|
Neuraminidase | 1 | 2019 | 192 | 0.160 |
Why?
|
Complement Fixation Tests | 1 | 2018 | 67 | 0.150 |
Why?
|
Pneumococcal Vaccines | 1 | 2022 | 414 | 0.150 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2021 | 296 | 0.150 |
Why?
|
Space Flight | 1 | 2021 | 219 | 0.150 |
Why?
|
Carbohydrates | 1 | 2020 | 387 | 0.150 |
Why?
|
Drug Administration Routes | 1 | 2018 | 152 | 0.150 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2022 | 549 | 0.150 |
Why?
|
Lung | 6 | 2023 | 10068 | 0.150 |
Why?
|
Receptors, KIR2DL3 | 2 | 2015 | 15 | 0.150 |
Why?
|
Sialic Acids | 1 | 2018 | 122 | 0.150 |
Why?
|
Pregnancy Trimester, Third | 1 | 2020 | 587 | 0.150 |
Why?
|
Antibody Diversity | 1 | 2017 | 72 | 0.150 |
Why?
|
Fucose | 1 | 2018 | 115 | 0.150 |
Why?
|
Signal Transduction | 6 | 2025 | 23618 | 0.150 |
Why?
|
Seasons | 1 | 2024 | 1519 | 0.150 |
Why?
|
Chronic Disease | 12 | 2016 | 9358 | 0.140 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 83 | 0.140 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 3 | 2011 | 25 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 6 | 2018 | 827 | 0.140 |
Why?
|
Microspheres | 3 | 2018 | 774 | 0.140 |
Why?
|
Nanoparticles | 4 | 2024 | 1966 | 0.140 |
Why?
|
Protein Array Analysis | 2 | 2016 | 399 | 0.140 |
Why?
|
Tumor Necrosis Factor-alpha | 7 | 2022 | 4349 | 0.140 |
Why?
|
Respiratory Mucosa | 1 | 2020 | 437 | 0.140 |
Why?
|
Mice, Inbred C57BL | 10 | 2021 | 22351 | 0.140 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2012 | 16044 | 0.140 |
Why?
|
Protein Precursors | 1 | 2021 | 1134 | 0.140 |
Why?
|
Trust | 1 | 2022 | 532 | 0.140 |
Why?
|
Galactose | 1 | 2018 | 299 | 0.140 |
Why?
|
Gene Frequency | 3 | 2016 | 3624 | 0.140 |
Why?
|
Cricetulus | 2 | 2018 | 810 | 0.140 |
Why?
|
Hospitalization | 4 | 2021 | 10816 | 0.140 |
Why?
|
Vibrio cholerae | 1 | 2023 | 793 | 0.140 |
Why?
|
Bayes Theorem | 3 | 2022 | 2353 | 0.140 |
Why?
|
Arthritis, Experimental | 1 | 2019 | 293 | 0.130 |
Why?
|
Cholera | 1 | 2023 | 754 | 0.130 |
Why?
|
Infectious Mononucleosis | 1 | 2016 | 133 | 0.130 |
Why?
|
Drug Design | 2 | 2015 | 1043 | 0.130 |
Why?
|
CD4 Lymphocyte Count | 6 | 2023 | 2586 | 0.130 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 647 | 0.130 |
Why?
|
Organ Specificity | 1 | 2021 | 1968 | 0.130 |
Why?
|
RNA Virus Infections | 1 | 2015 | 18 | 0.130 |
Why?
|
Burkitt Lymphoma | 1 | 2018 | 338 | 0.130 |
Why?
|
Viral Matrix Proteins | 1 | 2016 | 193 | 0.130 |
Why?
|
Down-Regulation | 3 | 2015 | 2931 | 0.120 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 1027 | 0.120 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1154 | 0.120 |
Why?
|
Immunocompromised Host | 1 | 2020 | 865 | 0.120 |
Why?
|
Transcription, Genetic | 4 | 2015 | 7612 | 0.120 |
Why?
|
Central Nervous System | 1 | 2022 | 1345 | 0.120 |
Why?
|
Myocarditis | 1 | 2023 | 802 | 0.120 |
Why?
|
B-Lymphocyte Subsets | 1 | 2016 | 240 | 0.120 |
Why?
|
Chemokine CXCL13 | 1 | 2015 | 62 | 0.120 |
Why?
|
Antigenic Modulation | 1 | 2014 | 11 | 0.120 |
Why?
|
Levonorgestrel | 1 | 2015 | 76 | 0.120 |
Why?
|
Interferon-alpha | 3 | 2015 | 910 | 0.120 |
Why?
|
Neoplasms | 3 | 2023 | 22350 | 0.120 |
Why?
|
Blood Bactericidal Activity | 1 | 2014 | 124 | 0.120 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2015 | 153 | 0.110 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2015 | 1529 | 0.110 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2015 | 116 | 0.110 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2016 | 317 | 0.110 |
Why?
|
Receptors, Virus | 1 | 2018 | 652 | 0.110 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4249 | 0.110 |
Why?
|
Blood Proteins | 1 | 2019 | 1194 | 0.110 |
Why?
|
Microscopy, Video | 2 | 2012 | 241 | 0.110 |
Why?
|
Mucus | 1 | 2016 | 346 | 0.110 |
Why?
|
Kinetics | 4 | 2022 | 6288 | 0.110 |
Why?
|
T-Box Domain Proteins | 1 | 2016 | 471 | 0.110 |
Why?
|
Age of Onset | 1 | 2021 | 3343 | 0.110 |
Why?
|
Autoimmunity | 1 | 2021 | 1361 | 0.110 |
Why?
|
Infant, Newborn, Diseases | 1 | 2019 | 587 | 0.110 |
Why?
|
Gestational Age | 1 | 2022 | 3617 | 0.110 |
Why?
|
Proviruses | 1 | 2015 | 319 | 0.110 |
Why?
|
Hypersensitivity | 1 | 2022 | 1168 | 0.110 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 588 | 0.110 |
Why?
|
Point Mutation | 2 | 2018 | 1592 | 0.100 |
Why?
|
Salmonella Infections | 1 | 2014 | 175 | 0.100 |
Why?
|
Apyrase | 1 | 2015 | 376 | 0.100 |
Why?
|
Receptors, Immunologic | 2 | 2011 | 1417 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2018 | 1186 | 0.100 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1380 | 0.100 |
Why?
|
B-Cell Activating Factor | 1 | 2013 | 116 | 0.100 |
Why?
|
Phenotype | 8 | 2022 | 16722 | 0.100 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2015 | 434 | 0.100 |
Why?
|
Antiviral Agents | 3 | 2020 | 3070 | 0.100 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2019 | 453 | 0.100 |
Why?
|
Molecular Sequence Data | 10 | 2015 | 17609 | 0.100 |
Why?
|
Glycomics | 1 | 2013 | 118 | 0.100 |
Why?
|
Chemokine CCL4 | 1 | 2012 | 126 | 0.100 |
Why?
|
Salmonella typhimurium | 1 | 2014 | 348 | 0.100 |
Why?
|
Staphylococcal Infections | 1 | 2021 | 1396 | 0.100 |
Why?
|
Bacterial Toxins | 1 | 2017 | 922 | 0.100 |
Why?
|
Receptors, KIR2DL2 | 1 | 2011 | 6 | 0.100 |
Why?
|
Intestines | 1 | 2021 | 1904 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1217 | 0.100 |
Why?
|
Proteomics | 3 | 2021 | 3915 | 0.100 |
Why?
|
Receptors, Interleukin-8A | 1 | 2011 | 47 | 0.100 |
Why?
|
Haplotypes | 2 | 2016 | 2726 | 0.100 |
Why?
|
Maternal Exposure | 1 | 2019 | 1096 | 0.100 |
Why?
|
Infection Control | 1 | 2018 | 984 | 0.090 |
Why?
|
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2010 | 14 | 0.090 |
Why?
|
Lymphopoiesis | 1 | 2012 | 133 | 0.090 |
Why?
|
Chemokines | 1 | 2015 | 963 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1791 | 0.090 |
Why?
|
Goals | 1 | 2016 | 717 | 0.090 |
Why?
|
Microfluidics | 1 | 2016 | 650 | 0.090 |
Why?
|
Fibrosis | 1 | 2018 | 2078 | 0.090 |
Why?
|
Citrate (si)-Synthase | 1 | 1990 | 48 | 0.090 |
Why?
|
Adenoviruses, Human | 1 | 2012 | 257 | 0.090 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 161 | 0.090 |
Why?
|
Receptors, CXCR5 | 3 | 2017 | 88 | 0.090 |
Why?
|
Inflammation Mediators | 2 | 2017 | 1889 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1642 | 0.090 |
Why?
|
Macrophages, Alveolar | 2 | 2025 | 413 | 0.090 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2010 | 56 | 0.090 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 195 | 0.090 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 144 | 0.090 |
Why?
|
Uridine | 2 | 2007 | 135 | 0.090 |
Why?
|
Bacterial Load | 2 | 2021 | 155 | 0.090 |
Why?
|
Vagina | 1 | 2016 | 849 | 0.090 |
Why?
|
Enzyme-Linked Immunospot Assay | 3 | 2016 | 126 | 0.090 |
Why?
|
Communicable Disease Control | 1 | 2016 | 857 | 0.080 |
Why?
|
Jurkat Cells | 3 | 2018 | 740 | 0.080 |
Why?
|
Mutation | 6 | 2020 | 30214 | 0.080 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2016 | 789 | 0.080 |
Why?
|
Homeostasis | 1 | 2021 | 3343 | 0.080 |
Why?
|
DNA | 2 | 2021 | 7210 | 0.080 |
Why?
|
Macaca fascicularis | 2 | 2024 | 908 | 0.080 |
Why?
|
Stem Cells | 2 | 2019 | 3536 | 0.080 |
Why?
|
Double-Blind Method | 7 | 2021 | 12430 | 0.080 |
Why?
|
Decision Trees | 1 | 2011 | 508 | 0.080 |
Why?
|
Substance Abuse, Intravenous | 1 | 2014 | 530 | 0.080 |
Why?
|
Cell Movement | 2 | 2011 | 5204 | 0.080 |
Why?
|
HIV Seronegativity | 2 | 2024 | 209 | 0.080 |
Why?
|
Animal Welfare | 2 | 2019 | 19 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2020 | 5306 | 0.080 |
Why?
|
Weight Loss | 1 | 2021 | 2712 | 0.080 |
Why?
|
Immunization Schedule | 2 | 2020 | 229 | 0.080 |
Why?
|
Preservation, Biological | 1 | 2008 | 26 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2952 | 0.080 |
Why?
|
Age Factors | 5 | 2024 | 18397 | 0.080 |
Why?
|
Solubility | 1 | 2010 | 1078 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2160 | 0.080 |
Why?
|
Biological Products | 1 | 2018 | 948 | 0.080 |
Why?
|
Phylogeny | 4 | 2021 | 2840 | 0.080 |
Why?
|
Receptors, Chemokine | 1 | 2011 | 652 | 0.080 |
Why?
|
Protein Isoforms | 1 | 2013 | 1716 | 0.070 |
Why?
|
Gene Expression Regulation | 4 | 2018 | 11924 | 0.070 |
Why?
|
Research | 1 | 2016 | 1977 | 0.070 |
Why?
|
Phlebotomy | 1 | 2008 | 138 | 0.070 |
Why?
|
Treatment Outcome | 10 | 2020 | 65286 | 0.070 |
Why?
|
Genes, MHC Class I | 2 | 2006 | 236 | 0.070 |
Why?
|
GPI-Linked Proteins | 1 | 2009 | 472 | 0.070 |
Why?
|
Massachusetts | 4 | 2020 | 8890 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15425 | 0.070 |
Why?
|
Lectins, C-Type | 1 | 2010 | 592 | 0.070 |
Why?
|
Cell Differentiation | 3 | 2018 | 11657 | 0.070 |
Why?
|
Skin | 1 | 2021 | 4499 | 0.070 |
Why?
|
Interleukin-17 | 2 | 2016 | 923 | 0.070 |
Why?
|
Sepsis | 1 | 2021 | 2604 | 0.070 |
Why?
|
Hepacivirus | 1 | 2014 | 1343 | 0.070 |
Why?
|
Nasal Mucosa | 2 | 2020 | 416 | 0.070 |
Why?
|
United States | 8 | 2024 | 72945 | 0.070 |
Why?
|
Toll-Like Receptor 8 | 1 | 2007 | 98 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2020 | 190 | 0.070 |
Why?
|
Genetic Variation | 3 | 2016 | 6613 | 0.070 |
Why?
|
Interferons | 2 | 2021 | 716 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2012 | 10451 | 0.070 |
Why?
|
Kenya | 2 | 2020 | 757 | 0.070 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2006 | 129 | 0.070 |
Why?
|
Macrophages | 3 | 2018 | 5784 | 0.060 |
Why?
|
Interleukin-12 | 1 | 2008 | 581 | 0.060 |
Why?
|
DNA Primers | 1 | 2010 | 2826 | 0.060 |
Why?
|
Regression Analysis | 3 | 2020 | 6329 | 0.060 |
Why?
|
Brain | 2 | 2024 | 27158 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5753 | 0.060 |
Why?
|
Clonal Anergy | 1 | 2006 | 169 | 0.060 |
Why?
|
Mass Spectrometry | 1 | 2013 | 2198 | 0.060 |
Why?
|
Lymphocytes | 3 | 2023 | 2606 | 0.060 |
Why?
|
HLA-A Antigens | 2 | 2005 | 223 | 0.060 |
Why?
|
Proteins | 1 | 2020 | 6002 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2018 | 2591 | 0.060 |
Why?
|
Lymphocytic choriomeningitis virus | 2 | 2016 | 176 | 0.060 |
Why?
|
Tanzania | 2 | 2024 | 1406 | 0.060 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1969 | 0.060 |
Why?
|
Indonesia | 1 | 2025 | 131 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 207 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 2930 | 0.060 |
Why?
|
Base Sequence | 2 | 2016 | 12415 | 0.060 |
Why?
|
Diarrhea | 2 | 2023 | 1317 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2015 | 2979 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1960 | 0.060 |
Why?
|
Genes, Viral | 1 | 2005 | 654 | 0.060 |
Why?
|
Vesiculovirus | 1 | 2023 | 53 | 0.050 |
Why?
|
Vaccines, Combined | 1 | 2023 | 70 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59548 | 0.050 |
Why?
|
Monkeypox virus | 1 | 2023 | 43 | 0.050 |
Why?
|
Chromosome Mapping | 1 | 2012 | 4618 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 21527 | 0.050 |
Why?
|
Antigens, Helminth | 1 | 2023 | 69 | 0.050 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9528 | 0.050 |
Why?
|
Biopsy | 2 | 2014 | 6779 | 0.050 |
Why?
|
Virulence | 2 | 2022 | 1294 | 0.050 |
Why?
|
Histocompatibility Antigens | 1 | 2004 | 479 | 0.050 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 880 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2011 | 4114 | 0.050 |
Why?
|
Open Reading Frames | 1 | 2006 | 818 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4050 | 0.050 |
Why?
|
Immunoglobulin Allotypes | 1 | 2022 | 52 | 0.050 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2007 | 582 | 0.050 |
Why?
|
Models, Biological | 4 | 2021 | 9464 | 0.050 |
Why?
|
DNA Copy Number Variations | 1 | 2011 | 2045 | 0.050 |
Why?
|
Sex Factors | 3 | 2024 | 10619 | 0.050 |
Why?
|
Virosomes | 1 | 2022 | 5 | 0.050 |
Why?
|
Protein Conformation | 3 | 2020 | 3948 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29959 | 0.050 |
Why?
|
Mice, Knockout | 4 | 2023 | 14473 | 0.050 |
Why?
|
Schistosoma mansoni | 1 | 2023 | 156 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 63 | 0.050 |
Why?
|
Measles virus | 1 | 2022 | 67 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 188 | 0.050 |
Why?
|
Hepatitis Delta Virus | 1 | 2021 | 24 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2020 | 9546 | 0.050 |
Why?
|
Encephalomyelitis, Equine | 1 | 2021 | 13 | 0.050 |
Why?
|
Measles Vaccine | 1 | 2022 | 79 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 4570 | 0.050 |
Why?
|
Encephalitis Virus, Eastern Equine | 1 | 2021 | 12 | 0.050 |
Why?
|
Comorbidity | 3 | 2021 | 10580 | 0.050 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2022 | 158 | 0.050 |
Why?
|
Peru | 1 | 2024 | 888 | 0.050 |
Why?
|
Drug Carriers | 2 | 2018 | 702 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2010 | 2328 | 0.050 |
Why?
|
alpha-Crystallins | 1 | 2020 | 4 | 0.050 |
Why?
|
Gene Order | 1 | 2021 | 166 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7475 | 0.040 |
Why?
|
Bangladesh | 1 | 2023 | 745 | 0.040 |
Why?
|
Horses | 1 | 2021 | 294 | 0.040 |
Why?
|
Liposomes | 1 | 2024 | 787 | 0.040 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2018 | 1677 | 0.040 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2023 | 415 | 0.040 |
Why?
|
U937 Cells | 1 | 2020 | 260 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2039 | 0.040 |
Why?
|
Peptide Library | 1 | 2021 | 351 | 0.040 |
Why?
|
Reference Values | 1 | 2007 | 4914 | 0.040 |
Why?
|
Joints | 1 | 2021 | 324 | 0.040 |
Why?
|
Antigenic Variation | 2 | 2012 | 117 | 0.040 |
Why?
|
Family Characteristics | 1 | 2025 | 1002 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2021 | 705 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8045 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2021 | 482 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 329 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 2020 | 256 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15652 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2021 | 445 | 0.040 |
Why?
|
Filoviridae Infections | 1 | 2019 | 6 | 0.040 |
Why?
|
CD40 Ligand | 1 | 2021 | 528 | 0.040 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2019 | 25 | 0.040 |
Why?
|
Permeability | 1 | 2021 | 721 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 13090 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5860 | 0.040 |
Why?
|
Immunogenetic Phenomena | 1 | 2018 | 23 | 0.040 |
Why?
|
Molecular Mimicry | 1 | 2020 | 212 | 0.040 |
Why?
|
Adenoviruses, Simian | 1 | 2018 | 16 | 0.040 |
Why?
|
Complement C1q | 1 | 2019 | 93 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 1 | 2019 | 464 | 0.040 |
Why?
|
Pteridines | 1 | 2018 | 47 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2022 | 618 | 0.040 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2019 | 113 | 0.040 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2021 | 546 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 638 | 0.040 |
Why?
|
Coronavirus | 1 | 2020 | 155 | 0.040 |
Why?
|
Mutant Proteins | 1 | 2020 | 487 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1574 | 0.040 |
Why?
|
Friend murine leukemia virus | 1 | 2017 | 37 | 0.040 |
Why?
|
Immune Sera | 1 | 2018 | 605 | 0.040 |
Why?
|
Malawi | 1 | 2019 | 312 | 0.040 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2022 | 426 | 0.040 |
Why?
|
Retrospective Studies | 6 | 2024 | 81657 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 381 | 0.040 |
Why?
|
Virus Attachment | 1 | 2018 | 56 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2021 | 1887 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2022 | 619 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 852 | 0.040 |
Why?
|
Virus Internalization | 1 | 2021 | 504 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3796 | 0.040 |
Why?
|
Retroviridae Infections | 1 | 2017 | 148 | 0.040 |
Why?
|
Nose | 1 | 2021 | 522 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 14073 | 0.040 |
Why?
|
Mammals | 1 | 2023 | 1133 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2022 | 6066 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10101 | 0.030 |
Why?
|
Pregnadienes | 1 | 1996 | 24 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26309 | 0.030 |
Why?
|
3T3 Cells | 1 | 2018 | 1082 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2021 | 2478 | 0.030 |
Why?
|
Binding Sites, Antibody | 1 | 2017 | 340 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 416 | 0.030 |
Why?
|
Orthomyxoviridae Infections | 1 | 2019 | 255 | 0.030 |
Why?
|
Convalescence | 1 | 2016 | 107 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 538 | 0.030 |
Why?
|
Sequence Analysis, DNA | 3 | 2016 | 4780 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12064 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2764 | 0.030 |
Why?
|
Biological Evolution | 1 | 2022 | 1075 | 0.030 |
Why?
|
Enterotoxins | 1 | 2017 | 366 | 0.030 |
Why?
|
Developed Countries | 1 | 2019 | 453 | 0.030 |
Why?
|
Cross Protection | 1 | 2015 | 25 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1838 | 0.030 |
Why?
|
Lectins | 1 | 2018 | 490 | 0.030 |
Why?
|
Oligopeptides | 1 | 2021 | 1195 | 0.030 |
Why?
|
Arenaviridae Infections | 1 | 2015 | 53 | 0.030 |
Why?
|
CHO Cells | 1 | 2018 | 1376 | 0.030 |
Why?
|
Workplace | 1 | 2022 | 873 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4860 | 0.030 |
Why?
|
Amniotic Fluid | 1 | 2017 | 381 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2021 | 1438 | 0.030 |
Why?
|
Prednisolone | 1 | 1996 | 326 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2020 | 3226 | 0.030 |
Why?
|
Transgenes | 1 | 2018 | 1014 | 0.030 |
Why?
|
Puerto Rico | 1 | 2016 | 380 | 0.030 |
Why?
|
Dizziness | 1 | 2018 | 269 | 0.030 |
Why?
|
Parturition | 1 | 2019 | 453 | 0.030 |
Why?
|
HIV Long Terminal Repeat | 1 | 2015 | 86 | 0.030 |
Why?
|
Program Development | 1 | 2021 | 1297 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 1 | 2018 | 588 | 0.030 |
Why?
|
Temperature | 1 | 2021 | 2231 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2016 | 426 | 0.030 |
Why?
|
Back Pain | 1 | 2018 | 547 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2295 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1010 | 0.030 |
Why?
|
Sequence Analysis, Protein | 1 | 2015 | 261 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1742 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2012 | 9613 | 0.030 |
Why?
|
Dependovirus | 1 | 2018 | 720 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 220 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2013 | 89 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2018 | 754 | 0.030 |
Why?
|
Protein Stability | 1 | 2015 | 578 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2018 | 1947 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 853 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2021 | 1429 | 0.030 |
Why?
|
Cattle | 1 | 2018 | 3815 | 0.030 |
Why?
|
Immunity, Mucosal | 1 | 2016 | 498 | 0.030 |
Why?
|
Uveitis | 1 | 1996 | 398 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 2085 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2016 | 2177 | 0.030 |
Why?
|
Interleukin-2 | 2 | 2012 | 1895 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1250 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2429 | 0.020 |
Why?
|
Africa | 1 | 2014 | 725 | 0.020 |
Why?
|
Immunologic Tests | 1 | 2012 | 101 | 0.020 |
Why?
|
Transfection | 2 | 2011 | 5755 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2018 | 1069 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2015 | 993 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2021 | 1761 | 0.020 |
Why?
|
Contraception | 1 | 2015 | 360 | 0.020 |
Why?
|
Immunoglobulin Variable Region | 1 | 2012 | 419 | 0.020 |
Why?
|
Canarypox virus | 1 | 2011 | 10 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2016 | 17089 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 940 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 18076 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1555 | 0.020 |
Why?
|
ras Proteins | 1 | 2016 | 1055 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2013 | 751 | 0.020 |
Why?
|
Genetic Engineering | 1 | 2016 | 936 | 0.020 |
Why?
|
Drosophila | 1 | 2018 | 1509 | 0.020 |
Why?
|
Receptors, KIR2DL1 | 1 | 2010 | 13 | 0.020 |
Why?
|
Income | 1 | 2019 | 1876 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2015 | 729 | 0.020 |
Why?
|
Receptors, HIV | 1 | 2010 | 159 | 0.020 |
Why?
|
Hydrogen Bonding | 1 | 1990 | 290 | 0.020 |
Why?
|
Recurrence | 2 | 2020 | 8507 | 0.020 |
Why?
|
Fetus | 1 | 2017 | 1878 | 0.020 |
Why?
|
Melanoma | 1 | 2008 | 5702 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2936 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6306 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1434 | 0.020 |
Why?
|
Histidine | 1 | 1990 | 301 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2062 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 1057 | 0.020 |
Why?
|
Homozygote | 1 | 2014 | 1775 | 0.020 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 41 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2008 | 62 | 0.020 |
Why?
|
Imidazoles | 1 | 2015 | 1168 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4401 | 0.020 |
Why?
|
Catalysis | 1 | 1990 | 767 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3853 | 0.020 |
Why?
|
Drosophila melanogaster | 1 | 2018 | 1725 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 149 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 1022 | 0.020 |
Why?
|
Health Status | 1 | 2021 | 4087 | 0.020 |
Why?
|
Interleukin-5 | 1 | 2008 | 268 | 0.020 |
Why?
|
Aspartic Acid | 1 | 1990 | 575 | 0.020 |
Why?
|
Immunomagnetic Separation | 1 | 2008 | 78 | 0.020 |
Why?
|
Receptors, CCR4 | 1 | 2008 | 77 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3828 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2887 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2510 | 0.020 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2008 | 202 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 229 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13276 | 0.020 |
Why?
|
Nanotechnology | 1 | 2012 | 702 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2008 | 151 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3885 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2008 | 243 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 1996 | 1805 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2721 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2215 | 0.020 |
Why?
|
Transcription Factors | 1 | 2006 | 12159 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2493 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10745 | 0.020 |
Why?
|
Virus Shedding | 1 | 2006 | 110 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2005 | 33 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 36 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2011 | 4168 | 0.020 |
Why?
|
Rats | 1 | 2021 | 23717 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6258 | 0.020 |
Why?
|
Research Design | 1 | 2021 | 6206 | 0.020 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 1 | 2006 | 146 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 363 | 0.020 |
Why?
|
Progesterone | 1 | 2009 | 752 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2018 | 4926 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2007 | 561 | 0.010 |
Why?
|
Linear Models | 1 | 2014 | 5873 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3957 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2744 | 0.010 |
Why?
|
Body Mass Index | 1 | 2021 | 13050 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1733 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5888 | 0.010 |
Why?
|
Caspase 3 | 1 | 2004 | 730 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13476 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2008 | 3759 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2023 | 15831 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2413 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9661 | 0.010 |
Why?
|
Caspases | 1 | 2004 | 881 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2008 | 1998 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7430 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2008 | 1646 | 0.010 |
Why?
|
Swine | 1 | 1990 | 5985 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2004 | 1750 | 0.010 |
Why?
|
Diet | 1 | 2017 | 8088 | 0.010 |
Why?
|
Escherichia coli | 1 | 1990 | 4211 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24299 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5795 | 0.010 |
Why?
|
Suspensions | 1 | 1996 | 68 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 3600 | 0.010 |
Why?
|
Anterior Chamber | 1 | 1996 | 194 | 0.010 |
Why?
|
Ophthalmic Solutions | 1 | 1996 | 312 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 74889 | 0.010 |
Why?
|
Administration, Topical | 1 | 1996 | 702 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12536 | 0.010 |
Why?
|
Safety | 1 | 1996 | 1157 | 0.010 |
Why?
|
Intraocular Pressure | 1 | 1996 | 1304 | 0.010 |
Why?
|